Ocular Therapeutix Q3: DEXTENZA revenue up 26% YoY to $15M; net loss narrows to $0.5M

OCULAR THERAPEUTIX, INC

2023-Q3 EPS reported -$0.77 revenue$43,642,000

DEXTENZA net product revenue $15.0M (+26% vs Q3 2022), in line with Q2 2023; full-year guidance raised to upper end of $55-60M.
Net loss improved to $(0.5M) or $(0.01) per basic share vs $(24.2M) loss in Q3 2022; diluted EPS $(0.25).
FDA agreed under Special Protocol Assessment to pivotal SOL trial for AXPAXLI (wet AMD); first patient dosing expected by year-end.
Cash and cash equivalents $110.6M as of Sept 30, 2023; management believes sufficient to fund operations into 2025.
Top-line data from HELIOS trial (NPDR) expected Q2 2024; Phase 2 data for OTX-TIC (glaucoma) expected April 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OCULAR THERAPEUTIX, INC reported third quarter ended September 30, 2023 results: revenue $15.0 million.

Period: third quarter ended September 30, 2023
Revenue: $15.0 million
Result: reported results

Exact text from the filing

Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Anticipated to be Presented at ASCRS Meeting in Early April 2024 DEXTENZA ® Net Product Revenue in Q3 2023 was $15.0 million, Representing Growth of Approximately 26% Over Q3 2022 BEDFORD, Mass.–(BUSINESS WIRE)— November 7, 2023 – Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company

View on SEC.gov

Browse all earnings releases →

OCULAR THERAPEUTIX, INC filing history →

Source: SEC EDGAR

accession 0001104659-23-115223

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.